Gufic Biosciences Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Gufic BioSciences Ltd is ₹ 299.65 as of 11 May 15:30 . The P/E Ratio of Gufic BioSciences Ltd changed from 33 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 41.4 on March 2024 to 28.1 on March 2023 . This represents a CAGR of -9.23% over 4 years The Market Cap of Gufic BioSciences Ltd changed from ₹ 2839 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 1050 crore on March 2024 to ₹ 554.6 crore on March 2023 . This represents a CAGR of -14.77% over 4 years The revenue of Gufic BioSciences Ltd for the Dec '25 is ₹ 232.2 crore as compare to the Sep '25 revenue of ₹ 239.17 crore. This represent the decline of -2.91% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Gufic BioSciences Ltd for the Dec '25 is ₹ 33.77 crore as compare to the Sep '25 ebitda of ₹ 39.96 crore. This represent the decline of -15.49% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Gufic BioSciences Ltd changed from ₹ 20.86 crore to ₹ 12.42 crore over 7 quarters. This represents a CAGR of -25.64% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Gufic BioSciences Ltd changed from 2.19 % on March 2021 to 1.43 % on March 2025 . This represents a CAGR of -8.17% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Gufic BioSciences Ltd

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients.
Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network.
The Company is ranked among the top 100 pharmaceutical companies in India. Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat.
The Company was incorporated in July, 1984.
The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Gufic BioSciences Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Gufic BioSciences Ltd or Syncom Formulations (India) Ltd?

Market cap of Gufic BioSciences Ltd is 3,004 Cr while Market cap of Syncom Formulations (India) Ltd is 1,353 Cr

What are the key factors driving the stock performance of Gufic BioSciences Ltd and Syncom Formulations (India) Ltd?

The stock performance of Gufic BioSciences Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gufic BioSciences Ltd and Syncom Formulations (India) Ltd?

As of May 12, 2026, the Gufic BioSciences Ltd stock price is INR ₹299.65. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.4.

How do dividend payouts of Gufic BioSciences Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Gufic BioSciences Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.